Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News NurExone Biologic Inc. V.NRX

Alternate Symbol(s):  NRXBF

Healthcare Biotechnology
NurExone Biologic Inc. is a biopharmaceutical company. The Company is developing and commercializing an exosome therapy ExoTherapy production platform and products for a global market. It is involved in the development of ExoPTEN, the first ExoTherapy-based product for acute Spinal Cord Injuries (SCI). The Company is developing treatment for the reversal or reduction of paralysis following... see more

Recent & Breaking News (TSXV:NRX)

NurExone Announces Interim Positive Results of Internal Preclinical Study of Proprietary ExoPTEN Drug

GlobeNewswire February 17, 2023

NurExone Biologic Inc. Emerges as a Promising Investment Opportunity in Biotechnology

GlobeNewswire February 13, 2023

United States Patent Office Allows Patent to Exosome Biomedical Company Nurexone

GlobeNewswire January 13, 2023

NurExone (TSXV:NRX) receives notice of allowance from United States Patent Office

Azuka Onwuka January 12, 2023

United States Patent Office Allows Patent to Exosome Biomedical Company NurExone

Newsfile January 12, 2023

NurExone Issues Annual Shareholder Letter

Newsfile December 15, 2022

NurExone Biologic (TSXV:NRX) completes securities-for-debt settlement

Azuka Onwuka December 8, 2022

NurExone Announces Completion of Securites for Debt Settlement

Newsfile December 7, 2022

Update: NurExone Biologic Successfully Demonstrates its Patent-Pending Platform Technology for Loading Exosomes with Therapeutic Molecules

Newsfile December 1, 2022

NurExone Biologic (TSXV:NRX) demonstrates its technology for loading exosomes with therapeutic molecules

Brieanna McCutcheon  November 30, 2022

NurExone Biologic Successfully Demonstrates its Patent-Pending Platform Technology for Loading Exosomes with Therapeutic Molecules

Newsfile November 30, 2022

NurExone Announces Securities for Debt Settlement

Newsfile November 24, 2022

NurExone (TSXV:NRX) reports Q3 2022 financial results & provides corporate update

Jonathon Brown November 24, 2022

NurExone Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Newsfile November 24, 2022

NurExone Announces Completion of Securities for Debt Settlements

Newsfile November 8, 2022

NurExone (TSXV:NRX) to submit pre-investigational drug meeting request to FDA

Brieanna McCutcheon  November 2, 2022

NurExone Announces Plan to Submit Pre-Investigational New Drug Meeting Request to U.S. Food and Drug Administration

Newsfile November 2, 2022

NurExone (TSXV:NRX) shares results from pilot testing of exosome treatment

Sabrina Cuthbert October 26, 2022

NurExone Announces Productivity and Quality Pilot Results of Patent-Pending Process for 3D Scaled Up Exosome Production

Newsfile October 26, 2022

NurExone Biologic to Participate in 2022 Bio-Europe Conference

Newsfile October 20, 2022